PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- GI 2.0: The Playbook | Industry Perspectives
- Disorders of Gut–Brain Interaction and the Rome V Process (Gastroenterology)
- Physician triage changed management in nearly 1 in 4 GI referrals (GI & Hepatology News)
- Upper GI Disorders: New Evidence May Refine Clinical Practice (Medscape)
- Pennsylvania Sues Chatbot Over Claims It Impersonates Doctors (MedCity News)
- Physician independence vanishes as corporate medicine swallows up U.S. health care (Medical Economics)
- Oshi Health Appoints Danny Krifcher as President and Chief Operating Officer (PR Newswire)
- Better onboarding may help GI practices retain APPs (GI & Hepatology News)
